Bio + Health

Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund

a16z editorial Posted January 14, 2025

Andreessen Horowitz (a16z) Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech Ecosystem Venture Fund (“Fund”) seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients’ lives. Managed by a16z Bio + Health, the Fund will deploy up to $500 million to invest in companies at all stages – from company creation to growth. The Fund will focus on advancing the development of new medicines, enabling novel modality platforms, and scaling emerging health technologies. As a complementary source of capital to traditional venture funding, the Fund will take a long-term view to enable disruptive companies to realize the full potential of new biological science, engineering technologies, and AI capabilities. The Fund aims to foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators.

Vineeta Agarwala, M.D., Ph.D, general partner at a16z Bio + Health, stated, “The Biotech Ecosystem Venture Fund seeks to enable visionary founders to create enduring solutions in biotech and healthcare. Combining our strengths as organizations will empower founders with not only the venture backing needed to advance groundbreaking technologies, but also the resources needed to strategically select the most promising application areas for these platforms. The creation of this new fund signifies a shared passion and commitment with Lilly to deliver truly meaningful change in our ability to treat and care for people living with disease.”

The Fund leverages the strengths of a16z in sourcing, building, and scaling bio + health companies, and combines it with Lilly’s deep expertise in life science R&D. Beyond contributing all the capital, Lilly will have the ability to provide additional resources to the companies, including Catalyze360TM which is a specialized support structure for biotech startups that includes Lilly Ventures, Lilly Gateway Labs, and Lilly ExplorR&DTM– all of which provide biotech startups with access to world-class pre-clinical and clinical drug development talent and resources. Together, a16z’s distinct experience at the intersection of life sciences and technology, and Lilly’s scientific, clinical, and commercial expertise create an alliance powered to overcome complex challenges within the healthcare ecosystem.

“Catalyze360 was created to accelerate the success of emerging biotech startups by providing access to people, tools, capabilities, and expertise that is traditionally hard for early-stage companies to reach,” said Nisha Nanda, Ph.D., group vice president, Catalyze360. “With the Biotech Ecosystem Fund, we can further scale our work to empower entrepreneurs as they work to bring transformative therapies to patients faster.”

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Bio + Health

Infinite Healthcare: What’s It Worth?

Jay Rughani, Jane Rhee, and Julie Yoo
General

Big Ideas in Tech for 2025

a16z editorial
Bio + Health

Consumers as a New Class of Payor

Julie Yoo

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.